___

• 1.Ramnath N, Dilling TJ, Harris LJ, Kim AW, Michaud GC, Balekian AA, et al. Treatment of stage III non-small cell lung cancer. Diag- nosis and management of lung cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2013;143(Suppl):e314S-40.
• 2.Bromley LL, Szur L. Combined radiotherapy and resection for carcino- ma of the bronchus; experiences with 66 patients. Lancet 1955;269:937- 41. [CrossRef]
• 3.Bloedorn FG, Cowley RA, Cuccia CA, Mercado R Jr, Wizenberg MJ, Linberg EJ. Preoperative irradiation in bronchogenic carcinoma. Am J Roentgenol Radium Ther Nucl Med 1964;92:77-87.
• 4.Warram J. Preoperative irradiation of cancer of the lung: final report of a therapeutic trial. A collaborative study. Cancer 1975;36:914-25. [CrossRef]
• 5.Wagner H Jr, Lad T, Piantadosi S, Ruckdeschel JC. Randomized phase 2 evaluation of preoperative radiation therapy and preoperative che- motherapy with mitomycin, vinblastine, and cisplatin in patients with technically unresectable stage IIIA and IIIB non-small cell cancer of the lung. LCSG 881. Chest 1994;106:S348-54. [CrossRef]
• 6.Elias AD, Kumar P, Herndon J 3rd, Skarin AT, Sugarbaker DJ, Green MR. Ra- diotherapy versus chemotherapy plus radiotherapy in surgically treated IIIA N2 non-small cell lung cancer. Clin Lung Cancer 2002;4:95-103. [CrossRef]
• 7.Eagan RT, Ruud C, Lee RE, Pairolero PC, Gail MH. Pilot study of induc- tion therapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) and chest irradiation prior to thoracotomy in initially inoperable stage III M0 non-small cell lung cancer. Cancer Treat Rep 1987;71:895-900.
• 8. Skarin A, Jochelson M, Sheldon T, Malcolm A, Oliynyk P, Overholt R, et al. Neoadjuvant chemotherapy in marginally resectable stage III M0 non-small cell lung cancer: long-term follow-up in 41 patients. J Surg Oncol 1989:40:266-74. [CrossRef]
• 9. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT 3rd, Weick JK, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stagesIIIA (N2) and IIIB non-small cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995;13:1880-92.
• 10. Faber LP, Kittle CF, Warren WH, Bonomi PD, Taylor SG 4th, Reddy S, et al. Preoperative chemotherapy and irradiationfor stage III non-small cell lung cancer. Ann Thorac Surg 1989;47:669-75. [CrossRef]
• 11. Law A, Karp DD, Dipetrillo T, Daly BT. Emergence of increased cere- bral metastasis after high-dose preoperative radiotherapy with chemo- therapy in patients with locally advanced nonsmall cell lung carcinoma. Cancer 2001;92:160-4. [CrossRef]
• 12. Strauss GM, Herndon JF, Sherman DD, Mathisen DJ, Carey RW, Choi NC, et al. Neoadjuvant chemotherapy and radiotherapy followed by sur- gery in stage IIIA non-small cell carcinoma of the lung: report of a Can- cer and Leukemia Group B phase II study. J Clin Oncol 1992;10:1237- 44.
• 13. Weiden PL, Piantodosi S. Preoperative chemotherapy (cisplatin and fluo- rouracil) and radiation therapy in stage III non-small cell lung cancer: A phase 2 study of the LCSG. Chest 1994;106(6Suppl):S344-7. [CrossRef]
• 14. Albain KS, Swann S, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resec- tion for stage III non-small-cell lung cancer: A phase III randomised controlled trial. Lancet 2009;374:379-86. [CrossRef]
• 15. Koshy M, Fedewa SA, Malik R, Ferguson MK, Vigneswaran WT, Feld- man L, et al. Improved survival associated with neoadjuvant chemoradi- ation in patients with clinical stage IIIA(N2) non-small-cell lung cancer. J Thorac Oncol 2013;8:915-22. [CrossRef]
• 16. Choi N, Carey R, Daly W, Mathisen D, Wain J, Wright C, et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small cell lung cancer. J Clin Oncol 1997;15:712-22.
• 17. Eberhardt W, Wilke H, Stamatis G, Stuschke M, Harstrick A, Menker H, et al. Preoperative chemotherapy followed by concurrent chemora- diation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small cell lung cancer: ma- ture results of a phase II trial. J Clin Oncol 1998;16:622-34.
• 18. Thomas M, Rübe C, Semik M, Macha HN, Freitag L, Linder A, et al. Impact of preoperative bimodality induction including twice-daily ra- diation on tumor regression and survival in stage III non-small-cell lung cancer. J Clin Oncol 1999;17:1185-93.
• 19. DeCamp MM, Rice TW, Adelstein DJ, Chidel MA, Rybicki LA, Murthy SC, et al. Value of accelerated multimodality therapy in stage IIIA and IIIB non-small cell lung cancer. J Thora Cardiovasc Surg 2003;126:17- 27. [CrossRef]
• 20. Thomas M, Rübe C, Hoffknecht P, Macha HN, Freitag L, Linder A, et al. Effect of preoperative chemoradiation in addition to preoperative che- motherapy: a randomised trial in stage III non-small cell lung cancer. Lancet Oncol 2008;9:636-48. [CrossRef]
• 21. Eberhardt WE, Gauler TC, Le Pechoux C, Stamatis G, Bildat S, Krbek T, et al. 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small cell lung cancer (NSCLC)-A multicenter phase-II trial (CIS- TAXOL). Lung Cancer 2013;82:83-9. [CrossRef]
• 22. Eberhardt WEE, Gauler TC, Pöttgen C, Friedel G, Veit S, Heinrich V, et al. Phase III study of surgery versus definitive concurrent chemo- radiotherapy boost in patients with operable stage IIIA(N2)/selected IIIB non-small cell lung cancer following induction chemotherapy and concurrent chemoradiotherapy (ESPATUE). J Clin Oncol 2014;32(15 Suppl):5s.
• 23. Pöttgen C, Eberhardt W, Graupner B, Theegarten D, Gauler T, Freitag L, et al. Accelerated hyperfractionated radiotherapy within trimodality therapy concepts for stage IIIA/B non-small cell lung cancer: markedly higher rate of pathologic complete remissions than with conventional fractionation. Eur J Cancer 2013;49:2107-15. [CrossRef]
• 24. Mauguen A, Le Péchoux C, Saunders MI, Schild SE, Turrisi AT, Baumann M, et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol 2012;30:2788-97. [CrossRef]
• 25. Fowler WC, Langer CJ, Curran WG, Keller SM. Postoperative complica- tions after combined neoadjuvant treatment of lung cancer. Ann Thorac Surg 1993;55:986-9. [CrossRef]
• 26. Sonett JR, Suntharalingam M, Edelman MJ, Patel AB, Gamliel Z, Doyle A, et al. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small cell lung cancer. Ann Thorac Surg 2004;78:1200-5. [CrossRef]
• 27. Cerfolio RJ, Bryant AS, Spencer SA, Bartolucci AA. Pulmonary resec- tion after high-dose and low-dose chest irradiation. Ann Thorac Surg 2005;80:1224-30. [CrossRef]
• 28. Daly BD, Fernando HC, Ketchedjian A, Dipetrillo TA, Kachnic LA, Morelli DM, et al. Pneumonectomy after high-dose radiation and con- current chemotherapy for nonsmall cell lung cancer. Ann Thorac Surg 2006;82:227-31. [CrossRef]
• 29. Suntharalingam M, Paulus R, Edelman MJ, Krasna M, Burrows W, Gore E, et al. Radiation Therapy Oncology Group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full- dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 2012;84:456-63. [CrossRef]
• 30. Grunenwald DH, AndréF, Le Péchoux C, Girard P, Lamer C, Laplanche A, et al. Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer. J Thorac Cardiovasc Surg 2001;122:796-802. [CrossRef]
• 31. Stupp R, Mayer M, Kann R, Weder W, Zouhair A, Betticher DC, et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in se- lected patients with stage IIIB non-small-cell lung cancer: A multicentre phase II trial. Lancet Oncol 2009;10:785-93. [CrossRef]